C. Proudlove
发表
Y. Dundar,
J. Hockenhull,
A. Bagust,
2013,
PharmacoEconomics.
M. Pirmohamed,
T. Walley,
D. Maxwell,
1993,
The Lancet.
Y. Dundar,
R. Dickson,
A. Bagust,
2011
.
A. Breckenridge,
R. Mann,
D. Back,
1988,
British journal of clinical pharmacology.
R. Plummer,
Y. Dundar,
R. Dickson,
2013,
PharmacoEconomics.
Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
C Proudlove,
Y. Dundar,
T. Brown,
2010,
Health technology assessment.
R. Shaw,
N. Fleeman,
Y. Dundar,
2009,
Health Technology Assessment.
J. Beresford,
C. Proudlove,
A. Flind,
1985,
The Lancet.
C Proudlove,
J Greenhalgh,
R. Kolamunnage-Dona,
2010,
Health technology assessment.
K. Dwan,
N. Fleeman,
Y. Dundar,
2014,
PharmacoEconomics.
K. Dwan,
N. Fleeman,
Y. Dundar,
2013
.
Y. Dundar,
J. Hockenhull,
A. Bagust,
2015,
PharmacoEconomics.
R. Moots,
P. Williamson,
N. Fleeman,
2009,
Health technology assessment.
Y. Dundar,
R. Dickson,
A. Bagust,
2011,
Health technology assessment.
T. Walley,
Y. Dundar,
R. Dickson,
2009,
Health Technology Assessment.
R. Shaw,
N. Fleeman,
Y. Dundar,
2012,
PharmacoEconomics.
K. Dwan,
A. Mullard,
M. Richardson,
2015,
Health technology assessment.
Y. Dundar,
R. Dickson,
J. Hockenhull,
2010
.
D. Mottram,
C. F. Green,
C. Randall,
1999
.
M. Walters,
J. Dawson,
Y. Dundar,
2011
.